A preliminary study suggests that melanomas have a different appearance than other irregular skin moles (i.e., are “ugly ducklings”), according to a report in the January issue of Archives of Dermatology, one of the JAMA/Archives journals.
Rates of malignant melanoma continue to increase, and early identification allows surgeons to treat the disease by removing the tumor, according to background information in the article. The disease is more common in individuals with many moles or other skin marks, especially if the marks are atypical in color, shape or size. “The challenge for clinicians who diagnose and treat pigmented skin lesions is to distinguish between malignant melanoma and benign simulants,” the authors write.
Alon Scope, M.D., of the Memorial Sloan-Kettering Cancer Center, New York, and colleagues obtained images of the backs of 12 patients from a database of standardized patient images. All of the patients had at least eight atypical moles, and five patients had one lesion that had been confirmed as a melanoma. Thirty-four study participants—including eight pigmented lesion experts, 13 general dermatologists, five dermatology nurses and eight non-clinical medical staff—were asked to evaluate the images and identify lesions that looked different from all other atypical moles.
All five melanomas and only three of 140 benign lesions (2.1 percent) were generally apparent as different, meaning that two-thirds of the participants identified them as “ugly ducklings.” “The malignant melanomas were apparent as being different to at least 85 percent of participants, whereas the agreement rate on the benign lesions perceived as being different was 76 percent at most,” the authors write. “Four lesions were generally apparent as completely different, all four being malignant melanomas.”
For all participants, the test had a sensitivity of 90 percent, meaning 90 percent of the melanomas were identified as different. Sensitivity was 100 percent for the pigmented lesion experts, 89 percent for general dermatologists, 88 percent for nurses and 85 percent for non-clinicians.
Source: JAMA and Archives Journals
Explore further: Mice study shows efficacy of new gene therapy approach for toxin exposures